News

A new indication for omalizumab is prompting clinicians to adjust their approach to oral food challenges, but experts ...
Current guidelines suggest limiting diagnostic testing for chronic spontaneous urticaria when no clear cause is suspected, though biomarkers and biopsies are emerging as tools to predict treatment ...
Food allergies affect up to 10% of the population in the USA and have been increasing in prevalence over the last 2–3 ...
Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...
Kashiv BioSciences, LLC today announced positive topline results from its confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR ® (omalizumab).
Omalizumab yields a high response rate and is generally well-tolerated in children with chronic spontaneous urticaria, according to the authors of a new study.
Omalizumab is a humanized monoclonal antibody that targets free immunoglobulin E (IgE). Xolair®, which contains omalizumab, is indicated for severe persistent allergic asthma, chronic rhinosinusitis ...
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) () | aktiencheck.deREYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 ...
Amneal Pharmaceuticals has announced positive topline results from a clinical trial for ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), which is being developed by Kashiv BioSciences.
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines ...
Kashiv BioSciences, LLC today announced positive topline results from its confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a prop ...